Hosted on MSN1d
Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders
India-based Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to ...
Suven Life spurts on initiating Phase-1 of clinical trial in US
Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...
The Financial Express1y
Suven Life Sciences Share Price
Suven Life Sciences Ltd. is a Public Limited Listed ... medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11.84 Cr. and Equity Capital is Rs.